Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Impact Assets Invests in Novobeing: Pioneering the Future of Digital Health and Well-being


BOSTON, Feb. 1, 2024 /PRNewswire/ -- Novobeing, an innovative digital health platform, is excited to announce an investment from Impact Assets, a leader in impact investing. This partnership marks a pivotal moment in Novobeing's mission to revolutionize stress management and enhance well-being, through state-of-the-art virtual and mixed-reality solutions.

Founded with a vision to redefine how people combat stress, Novobeing blends cutting-edge technology with scientifically validated methods. Their unique approach offers personalized, immersive experiences that cater to individual needs, setting a new standard in the realm of digital health. The company's platform is designed to increase engagement and efficacy of proven stress reduction and well-being treatments like meditation, breathwork and cognitive behavioural therapy. Novobeing prioritizes personalization, enabling users to tailor their experience to suit individual conditions, emotional states, and stress levels, making it an adaptable solution for both healthcare and personal use.

Designed to meet the rigorous demands of healthcare environments, Novobeing's solutions are currently deployed in six hospitals and are the subject of three clinical trials. With an early access application available for individual users on the Meta Quest and an enterprise stress reduction kit for healthcare providers, Novobeing is at the forefront of integrating immersive technology into mental health and well-being practices.

The investment from Impact Assets, known for its commitment to creating positive social and environmental impact, is a testament to Novobeing's potential to make a significant difference in people's lives. With over $3 billion in assets under management and a focus on innovative solutions, Impact Assets recognizes the transformative power of Novobeing's platform. This investment decision was guided by rigorous due diligence spearheaded by the Harvard Business School Investment for Impact program.

This strategic investment will accelerate Novobeing's product development and innovation, enabling them to expand their reach and impact. The collaboration aligns with Impact Assets' goal to support initiatives that contribute to a better world, emphasizing their belief in Novobeing's capacity to drive meaningful change in the health and wellness sector.

"We are thrilled to have Impact Assets as a partner in our journey," said Sid Desai, CEO of Novobeing. "Their belief in our vision and commitment to social change resonates deeply with our core values. This investment is not just a financial boost but a validation of our efforts to transform stress management and well-being."

About Novobeing 
Novobeing is a digital health platform that delivers science-backed immersive stress management solutions. We are redefining the way people deal with stress and enhance their well-being through highly engaging and personalized virtual and mixed-reality experiences.

For more information about Novobeing visit https://www.novobeing.com/
To learn more about Impact Assets visit https://impactassets.org/

SOURCE Novobeing Inc.


These press releases may also interest you

30 jun 2024
NOVOSENSE Microelectronics, a global automotive chip provider, recently announced the launch of its latest product collection, delivering high-quality solutions tailored for automotive lighting, powertrain, BMS, thermal management systems. Advanced...

30 jun 2024
KKR, a leading global investment firm, and Teachers' Venture Growth (TVG), the late-stage venture and growth investment arm of Ontario Teachers' Pension Plan, today announced the signing of definitive agreements under which KKR (on behalf of funds...

30 jun 2024
At a recent event in Shanghai, Squirrel Ai unveiled its latest achievement: a multimodal Large Adaptive Model (LAM) that represents a major step forward in educational technology. The conference revealed significant upgrades to both the model and the...

30 jun 2024
Pomelo Group is proud to announce the endorsement of...

30 jun 2024
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...



News published on and distributed by: